Atrial fibrillation: Effective strategies using the latest tools

Direct oral anticoagulants or warfarin? Rate or rhythm control? Here’s how to determine which strategies to pursue and when.

Atrial fibrillation (AF)—the most common supraventricular tachycardia—affects as many as 6.1 million adults in the United States. It is associated with a 5-fold increased risk of stroke, a 3-fold increased risk of heart failure (HF), and about a 2-fold increased risk of dementia and mortality. The prevalence of AF increases with maturity, from 2% in people <65 years of age to 9% in those ≥65 years, and that prevalence is expected to double over the next 25 years as the population ages.

The primary goals of treatment are to alleviate symptoms and prevent thromboembolism. Strokes related to AF are more likely to result in severe disability or death when compared with those unrelated to AF. Anticoagulation remains underutilized. The net clinical benefit of oral anticoagulation appears to be greatest in patients with the highest risk of bleeding, since these patients are also at the highest risk for stroke. Patients at increased risk of stroke are more likely to receive oral anticoagulation; however, for unknown reasons, more than half of people with the highest risk of stroke are not prescribed these important anti-blood-clotting medications. One theory is that physicians may be relying on their gut rather than objective risk scores, and underuse of validated schemata leads to poor estimation of risk.

For example, results from the ORBIT-AF (Outcomes Registry for Better Informed Treatment of Atrial Fibrillation) trial, which involved over 10,000 people with AF, found that although 72% (n=7251) had high-risk CHADS₂ scores (≥2), only 16% were assessed as having a high risk of stroke by physicians. Along the same lines, a recent study of Canadian primary care physicians showed that stroke risk and bleeding risk were not evaluated with validated tools in 58% and 81% of patients, respectively, leading to both significant underestimation and overestimation of risk.

This review provides the tools to identify when anticoagulation is indicated, reports the advantages and dis-

**PRACTICE RECOMMENDATIONS**

- Use the CHA₂DS₂-VASc score to assess the risk of thromboembolism, including ischemic stroke. 
- Consider prescribing a direct oral anticoagulant (DOAC) instead of warfarin for patients with nonvalvular atrial fibrillation (AF) because they are superior at preventing strokes and lowering all-cause mortality in this population. 
- Do not use a DOAC in patients with mechanical heart valves, hemodynamically significant mitral stenosis, or severe chronic kidney disease (estimated glomerular filtration rate [eGFR] <30 mL/min/1.73 m²). 
- Pursue a rate-control strategy for most patients with AF, although rhythm control may be preferable for younger (<65 years) symptomatic patients.

**Strength of recommendation (SOR)**

- Good-quality patient-oriented evidence
- Inconsistent or limited-quality patient-oriented evidence
- Consensus, usual practice, opinion, disease-oriented evidence, case series
advantages of the currently available anticoagulants, and discusses the selection and implementation of rate- vs rhythm-control strategies. But first, a word about the etiology, classification, and diagnosis of AF.

**AF: The result of any number of cardiac and non-cardiac causes**

AF is characterized by uncoordinated activation of the atria, which results in ineffective atrial contractions and an irregular, often rapid, ventricular response. It is the ultimate clinical manifestation of multiple diseases that alter atrial tissue through inflammation, fibrosis, or hypertrophy. The most common causes are hypertension, coronary artery disease, HF, cardiomyopathies, and valvular heart disease, all of which stimulate the renin-angiotensin-aldosterone system, leading to increased susceptibility to arrhythmia. Atrial ectopic tachycardia, Wolff-Parkinson-White (WPW) syndrome, and atrioventricular (AV) nodal reentrant tachycardia also may precipitate AF. In these cases, AF usually resolves after catheter ablation (CA) of the primary arrhythmia. Unrecognized AF may trigger atrial flutter, and more than 80% of patients who undergo radiofrequency ablation for atrial flutter experience AF at some point in the subsequent 5 years.

Non-cardiac causes of AF include sleep apnea, obesity, hyperthyroidism, drugs, electrocution, pneumonia, and pulmonary embolism. An association between binge drinking and AF (“holiday heart syndrome”) has long been recognized. The evidence now suggests that alcohol increases the risk of AF in a dose-dependent manner with intakes of ≥1 drink per day (12 g per drink).

**Classification schema no longer includes “lone AF”**

AF is classified in terms of the duration of episodes:

- **Paroxysmal AF** is characterized by brief episodes that terminate spontaneously or with intervention within 7 days of onset. These episodes recur with variable frequency.
- **Persistent AF** refers to AF that is continuously sustained for more than 7 days.
- **Longstanding persistent AF** refers to continuous AF that lasts longer than 12 months.

Strokes related to atrial fibrillation are more likely to result in severe disability or death when compared with those unrelated to AF. And yet anticoagulation remains underutilized.
• **Permanent AF** is not an inherent pathophysiologic attribute of AF, but rather an acceptance of AF where the patient and physician abandon further efforts to restore and/or maintain sinus rhythm.

• **Nonvalvular AF** occurs in the absence of a valve replacement (mechanical or bioprosthetic), rheumatic mitral stenosis, or mitral valve repair.

Although paroxysmal and persistent AF may occur in the same individual, the distinction is still clinically relevant, as outcomes of certain therapies, such as CA, are superior in patients with paroxysmal AF. With a more complete understanding of AF pathophysiology, guidelines now discourage use of the potentially confusing term “lone AF,” which has historically been applied to younger patients with no known clinical risk factors or echocardiographic abnormalities. As a result, therapeutic decisions are no longer based on this nomenclature, according to the 2014 AF practice guideline from the American College of Cardiology (ACC)/American Heart Association (AHA)/Heart Rhythm Society (HRS).

**Patient complaints—or incidental findings—can prompt a Dx**

Fatigue is the most common symptom of AF. Other signs and symptoms include palpitations, dyspnea, HF, hypotension, syncope, chest pain, and stroke. Some patients are asymptomatic, and AF is an incidental finding when an irregular pulse is discovered during a physical examination. The diagnosis is confirmed by electrocardiogram (EKG), telemetry, Holter monitor, event recorder, or an implanted electrocardiographic recording device. A chest x-ray, serum electrolyte levels, a complete blood count, thyroid testing, and renal and hepatic function testing are recommended. Transthoracic echocardiography to measure cardiac function, detect underlying structural heart disease, and evaluate atrial size is essential.

An electrophysiologic (EP) study may be needed for diagnosis or treatment if another arrhythmia is present. Aberrant conduction may cause AF to present as a wide complex tachycardia and be mislabeled as ventricular tachycardia. The presence of delta waves is an indication for an EP study targeting the WPW accessory pathway. Transesophageal echocardiography (TEE) is the most sensitive and specific test for left atrial thrombi. If you are considering a TEE for a patient with AF of unknown, or >48 hours, duration who has not been anticoagulated in the preceding 3 weeks, obtain it before performing cardioversion because of the risk of embolism.

**Stroke prevention**

The ACC/AHA/HRS AF guideline recommends basing anticoagulation decisions on thromboembolic risk, regardless of AF pattern (paroxysmal, persistent, or permanent) (Class I recommendation). For patients with nonvalvular AF and atrial flutter, the guideline recommends using the Birmingham 2009 schema (CHA\(2\)_DS\(2\)_VASc score) (TABLE 1) to estimate thromboembolic risk. CHA\(2\)_DS\(2\)_VASc improves on the older CHADS\(2\) score by significantly reducing the number of patients categorized as having intermediate risk and better identifying truly low-risk patients who are unlikely to benefit from anticoagulation.

Men with a CHA\(2\)_DS\(2\)_VASc score of zero and women with a score of one do not need anticoagulation. Discuss the risks and benefits of oral anticoagulation with men who have a score of one. In these intermediate-risk men, antiplatelet therapy with aspirin and/or clopidogrel may be reasonable, especially if there is an indication other than stroke prevention (eg, postmyocardial infarction). Oral anticoagulation is strongly recommended for all patients with a CHA\(2\)_DS\(2\)_VASc score of 2 or higher.

**Anticoagulant considerations:**

**Warfarin vs DOACs**

Warfarin was the gold standard for stroke prevention in nonvalvular AF until the direct oral anticoagulants (DOACs) became available in 2010. Guidelines in the United States and the United Kingdom recommend shared decision-making to help patients with AF who do not have a specific indication for warfarin choose between warfarin and the
DOACs. 5,21 Canadian and European guidelines recommend DOACs as the first-line option for anticoagulation and reserve warfarin for patients who have contraindications to, or are unable to afford, DOACs. 18,22 All current guidelines recommend continuing warfarin in patients who are stable, well controlled, and satisfied with warfarin therapy and the monitoring and dietary restrictions it entails.

**DOACs are as effective as warfarin.** All of the DOACs are approved for stroke prevention based on individual phase III non-inferiority trials in which they were compared to warfarin. 23-26 In addition, a meta-analysis of these 4 trials involving a total of 71,683 patients (mean age 70-73 years; median follow-up, 1.8-2.8 years) evaluated the benefits and risks of the 4 DOACs against the former gold standard. 27

Higher doses of the DOACs (dabigatran 150 mg BID, rivaroxaban 20 mg/d, edoxaban 60 mg/d, and apixaban 5 mg BID) reduced the rates of stroke or systemic embolism (relative risk [RR]=0.81; 95% confidence interval [CI], 0.73-0.91; P<.0001; number needed to treat [NNT]=147), hemorrhagic stroke (RR=0.49; 95% CI, 0.38-0.64; P<.0001; NNT=219), and all-cause mortality (RR=0.90; 95% CI, 0.85-0.95; P=.0003; NNT=128), compared with warfarin. 27 It is important to note that while lower doses of some DOACs (dabigatran 110 mg BID and edoxaban 30 mg/d) were not as effective at preventing ischemic stroke when compared with warfarin (RR=1.3; 95% CI, 1-1.6; P=.045), they still significantly reduced hemorrhagic stroke (RR=0.33; 95% CI, 0.23-0.46; P<.0001) and all-cause mortality (RR=0.89; 95% CI, 0.83-0.96; P=.003).

**Of course, the biggest concern is bleeding.** In that same meta-analysis, the difference in major bleeding events with DOACs vs warfarin was not statistically significant (RR=0.86; 95% CI, 0.73-1; P=.06). While DOACs likely lower rates of intracranial hemorrhage (RR=0.48; 95% CI, 0.39-0.59; P<.0001; NNT=132), they seem to increase the risk of gastrointestinal (GI) bleeding (RR=1.3; 95%
Without head-to-head trials, it is impossible to know if one direct oral anticoagulant is superior to another.

There was significant heterogeneity in the GI bleeding outcome, however. When compared with warfarin, GI bleeding was increased by dabigatran 150 mg BID (RR=1.5; 95% CI, 1.2-1.9; P<.001) and edoxaban 60 mg/d (HR=1.2; 95% CI, 1.02-1.5; P=.03), but there were no significant differences for dabigatran 110 mg BID or apixaban 5 mg BID.27

On the other hand, edoxaban 30 mg/d had a lower risk of GI bleeding when compared with warfarin (HR=0.67; 95% CI, 0.53-0.83; P<.001).25 Without head-to-head trials, it is impossible to know if one DOAC is superior to another. Apixaban 5 mg BID appears to offer the best overall balance between efficacy and safety. Other DOACs may be better options for patients who have specific concerns regarding efficacy or safety.28,29

Convenience, interactions, and cost may be the deciding factors. Since all DOACs are fairly comparable in efficacy and safety, other factors such as convenience, interactions with other medications, and cost should be considered when deciding on a medication for an individual patient (TABLE 2).25,31 The DOACs require no lab monitoring or dose titration, and all 4 have fewer potential drug interactions than warfarin.30 Due to their relatively short half-lives, strict adherence is critical; DOACs are not suitable for patients who frequently miss doses.5 (For more information on starting or switching to DOACs, see, “Is a novel anticoagulant right for your patient?” J Fam Pract. 2014;63:22-28.)

A word about DOACs and renal impairment. Another concern with DOACs is their reliance on renal metabolism and excretion. A meta-analysis of the 4 phase III trials of the DOACs, this time involving 58,338 patients, evaluated DOAC efficacy and safety compared to warfarin in the presence of kidney dysfunction.22 Renal function was categorized as normal (estimated glomerular filtration rate [eGFR] >80 mL/min/1.73 m²), mildly impaired (eGFR 50-80 mL/min/1.73 m²), or moderately impaired (eGFR <50 mL/min/1.73 m²). Compared with warfarin, DOACs lowered stroke risk in patients with mild (RR=0.71; 95% CI, 0.62-0.81) or moderate (RR=0.79; 95% CI, 0.66-0.94) renal impairment. DOACs also reduced major bleeding compared to warfarin in patients with mild (RR=0.88; 95% CI, 0.80-0.97) or moderate (RR=0.80; 95% CI, 0.66-0.94) renal impairment. How the DOACs fare in patients with severe renal dysfunction could not be determined because such patients were excluded from the trials.

Keep in mind that the DOACs require dose adjustment at different levels of renal impairment (TABLE 2),26,31 and warfarin remains the only recommended treatment for patients with severe renal impairment, according to both AHA/ACC/HRS and European Society of Cardiology guidelines.5,18

Tools to help assess patients’ bleeding risk

Of the available scoring mechanisms to identify risk factors for bleeding, 3 have been specifically validated in AF populations (ie, ATRIA,33 HEMORR 2HAGES,34 and HAS-BLED35). Of the 3, HAS-BLED is superior,36 the most practical, and recommended by expert guidelines.18,21,22 Additionally, HAS-BLED has good correlation with intracranial hemorrhage risk. The HAS-BLED score ranges from 0 to 9 points with one point assigned for each of the following:35

- **Hypertension**—uncontrolled with systolic BP >160 mm Hg
- **Abnormal liver function**—cirrhosis, bilirubin >2X normal, or liver enzymes >3X normal
- **Abnormal renal function**—dialysis, transplant, or serum creatinine >2.26 mg/dL
- **Stroke history**—including lacunar infarcts
- **Bleeding predisposition**—history of major bleeding due to any cause
- **Labile international normalized ratio (INR)**—time in therapeutic range <60%
- **Elderly**—age >65 years
- **Drug**—antiplatelet agents, including nonsteroidal anti-inflammatory drugs
- **Alcohol usage**—>8 drinks per week.

Patients with a HAS-BLED score ≥3 warrant additional monitoring and attempts...
to reduce bleeding risk by addressing modifiable risk factors. Bleeding risk scores should not be used to exclude patients from anticoagulation therapy.\textsuperscript{5} In fact, the British National Institute for Health and Clinical Excellence (NICE) guidelines state that anticoagulation should not be withheld solely due to fall risk.\textsuperscript{21}

Also, anticoagulation with warfarin should not be permanently discontinued because of a single GI bleed, since restarting warfarin is associated with decreased risks of thromboembolism and mortality and a statistically insignificant increase in recurrent GI bleeding.\textsuperscript{37} Restarting DOAC therapy following a GI bleed has not been evaluated in clinical trials; however, it may be reasonable to use one of the DOAC doses with a lower risk of GI bleeding (dabigatran 110 mg BID, apixaban 5 mg BID, or edoxaban 30 mg/d) in patients who have experienced a GI bleed on warfarin or another DOAC.\textsuperscript{18,22}

An online calculator is available that uses CHA\textsubscript{2}-DS\textsubscript{2}-VASc and HAS-BLED scores to determine an individual’s risk/benefit profile with the various anticoagulation strategies available (http://www.sparctool.com). Consider percutaneous left atrial appendage occlusion if the risks of anticoagulation truly exceed the benefits.\textsuperscript{38}

\textbf{Rate control vs rhythm control}

Most patients who present with AF require immediate ventricular rate control to reduce symptoms. In the acute setting, this can be accomplished with intravenous (IV) beta-blockers or IV calcium channel antagonists.\textsuperscript{5,39} If the patient is hemodynamically unstable, urgent direct-current cardioversion

\begin{table}
\centering
\caption{Pharmacologic characteristics of the direct oral anticoagulants\textsuperscript{30,31}}
\begin{tabular}{|c|c|c|c|c|}
\hline
\textbf{Medication} & \textbf{Dabigatran} & \textbf{Rivaroxaban} & \textbf{Edoxaban} & \textbf{Apixaban} \\
\hline
\textbf{Mechanism of action} & Direct thrombin inhibitor & Direct factor Xa inhibitor & Direct factor Xa inhibitor & Direct factor Xa inhibitor \\
\hline
\textbf{Dosing for NVAF} & 150 mg BID & 20 mg/d with the evening meal & 60 mg/d* & 5 mg BID; or 2.5 mg BID if 2 of the following are present: SCr $\geq$1.5 mg/dL, age $\geq$80 years, weight $\leq$60 kg \\
\hline
\textbf{Moderate renal impairment (CrCl 30-50 mL/min)} & 150 mg BID; or 75 mg BID when combined with dronedarone or oral ketoconazole & 15 mg/d with the evening meal & 30 mg/d & \\
\hline
\textbf{Severe renal impairment (CrCl 15-30 mL/min)} & Not recommended & 15 mg/d with the evening meal & 30 mg/d & Not recommended for CrCl$\leq$25 mL/min \\
\hline
\textbf{End-stage CKD (CrCl $<$15 mL/min)} & Not recommended & Not recommended & Not recommended & Not recommended \\
\hline
\textbf{Half-life (hours)} & 13-27 & 5-9 & 10-14 & 3-4 \\
\hline
\textbf{Protein binding} & 35\% & 92\%-95\% & 55\% & 87\% \\
\hline
\textbf{CYP enzyme metabolism}\textsuperscript{*} & No & Yes & Yes & Yes \\
\hline
\textbf{P-gp transport} & Yes & No & Yes & Yes \\
\hline
\textbf{Renal excretion} & 80\% & 66\% & 50\% & 27\% \\
\hline
\textbf{Cost per month} & $379 & $389 & $323 & $389 \\
\hline
\end{tabular}
\textsuperscript{CKD, chronic kidney disease; CrCl, creatinine clearance; CYP, cytochrome P450; NVAF, nonvalvular atrial fibrillation; P-gp, P-glycoprotein; SCr, serum creatinine. *Not recommended for CrCl$>$95 mL/min. \\
\textsuperscript{1}Some of the more common P450 drug interactions include: antifungals (ketoconazole, itraconazole), protease inhibitors (lopinavir, ritonavir, indinavir), antiepileptics (carbamazepine, phenytoin), and antibiotics (clarithromycin).}
\end{table}
is the preferred treatment strategy and should not be delayed pending anticoagulation. IV amiodarone can be used in the ICU patient who does not require cardioversion, but is unable to tolerate beta-blockers or calcium channel antagonists.40 Once the patient is stable, long-term treatment focuses on ventricular rate control or restoration and maintenance of sinus rhythm.

The AFFIRM (Atrial Fibrillation Follow-up Investigation of Rhythm Management) trial enrolled 4060 patients (mean age 70 years, mean follow-up 3.5 years) with paroxysmal AF and persistent AF, and randomized patients to rate control or rhythm control.41 Rates of death, stroke, and bleeding were similar between the two groups, with no difference in the primary endpoint of death, stroke, or bleeding. However, the rate of hospitalization for heart failure was higher in the rhythm control group, suggesting that rate control may be a safer strategy for patients with concomitant heart failure.

### TABLE 3
A review of rate- and rhythm-control medications

<table>
<thead>
<tr>
<th>Drug</th>
<th>Loading dose</th>
<th>Maintenance dose</th>
<th>Specific indications</th>
<th>Cautions or adverse effects</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Rate Control</strong></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td><strong>Beta-blockers</strong></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Atenolol</td>
<td>N/A</td>
<td>25-100 mg/d</td>
<td>None</td>
<td>Blunts response to exercise</td>
</tr>
<tr>
<td>Bisoprolol</td>
<td>N/A</td>
<td>2.5-10 mg/d</td>
<td>HFrEF</td>
<td>Contraindicated in the presence of bradycardia, pre-excitation,* decompensated HF</td>
</tr>
<tr>
<td>Carvedilol</td>
<td>N/A</td>
<td>3.125-25 mg BID</td>
<td>HFrEF</td>
<td></td>
</tr>
<tr>
<td>Esmolol</td>
<td>500 mcg/kg bolus IV over 1 min, then 50-300 mcg/kg/min IV</td>
<td>N/A</td>
<td>Short duration, use if uncertain that beta-blocker will be tolerated</td>
<td></td>
</tr>
<tr>
<td>Metoprolol succinate (XL)</td>
<td>N/A</td>
<td>50-400 mg/d</td>
<td>Used in high adrenergic tone (ie, post-operative AF)</td>
<td></td>
</tr>
<tr>
<td>Metoprolol tartrate</td>
<td>2.5-5.0 mg IV bolus over 2 min (Max: 3 doses)</td>
<td>25-100 mg BID</td>
<td>Following acute MI HFrEF (only XL)</td>
<td></td>
</tr>
<tr>
<td>Nadolol</td>
<td>N/A</td>
<td>10-240 mg/d</td>
<td>None</td>
<td></td>
</tr>
<tr>
<td>Propranolol</td>
<td>1 mg IV over 1 min, up to 3 doses at 2-min intervals</td>
<td>10-40 mg TID or QID</td>
<td>None</td>
<td></td>
</tr>
<tr>
<td><strong>Non-dihydropyridine CCBs</strong></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Diltiazem</td>
<td>0.25 mg/kg IV bolus over 2 min, then 5-15 mg/hr</td>
<td>120-360 mg/d (ER)</td>
<td>Chronic obstructive pulmonary disease Asthma</td>
<td>Contraindicated in the presence of HFrEF or pre-excitation*</td>
</tr>
<tr>
<td>Verapamil</td>
<td>0.075-0.15 mg/kg IV bolus over 2 min; may give additional 10 mg after 30 min if no response, then 0.005 mg/kg/min infusion</td>
<td>180-480 mg/d (ER)</td>
<td>Asthma</td>
<td></td>
</tr>
<tr>
<td><strong>Other</strong></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Amiodarone</td>
<td>300 mg IV over 1 hr, then 10-50 mg/hr over 24 hr</td>
<td>100-200 mg/d</td>
<td>HFrEF</td>
<td>Pre-excitation*</td>
</tr>
<tr>
<td>Digoxin†</td>
<td>0.25 mg IV with repeat dosing (Max: 1.5 mg in 24 hr)</td>
<td>0.125-0.25 mg/d</td>
<td>HFrEF Additive when combined with beta-blocker or CCB</td>
<td>Not optimal for rapid control Pre-excitation*</td>
</tr>
</tbody>
</table>

AF, atrial fibrillation; AV, atrioventricular; CAD, coronary artery disease; CCB, calcium channel blocker; CNS, central nervous system; ER, extended release; GI, gastrointestinal; HCM, hypertrophic cardiomyopathy; HF, heart failure; HFrEF, heart failure with reduced ejection fraction; INR, international normalized ratio; IR, immediate release; IV, intravenous; LV, left ventricle; MI, myocardial infarction; NA, not applicable; XL, extended release.

*IV procainamide or ibutilide are the agents of choice for AF with pre-excitation.
†Dose adjustments are required in renal dysfunction, the elderly, and with some medications.
‡Use of one of these Class IC antiarrhythmic drugs (in addition to a beta-blocker or CCB) is a reasonable outpatient strategy for AF termination (in symptomatic patients with infrequent paroxysmal AF) after proven safe and effective in a monitored setting.
### TABLE 3
A review of rate- and rhythm-control medications\(^5\) *(continued)*

<table>
<thead>
<tr>
<th>RHYTHM CONTROL</th>
</tr>
</thead>
<tbody>
<tr>
<td>Drug</td>
</tr>
<tr>
<td>Class IC – For cardioversion, give beta-blocker or CCB ≥30 min prior to a IC agent(^4)</td>
</tr>
<tr>
<td>Flecainide</td>
</tr>
<tr>
<td>Propafenone</td>
</tr>
<tr>
<td>Class III</td>
</tr>
<tr>
<td>Amiodarone</td>
</tr>
<tr>
<td>Dofetilide</td>
</tr>
<tr>
<td>Sotalol</td>
</tr>
</tbody>
</table>
them to either pharmacologic rate control or rhythm control. No significant differences were found in all-cause mortality or in the composite secondary endpoint of death, ischemic stroke, anoxic encephalopathy, major bleeding, or cardiac arrest. In addition, no significant differences emerged in quality of life or global functional status. The number of patients requiring hospitalization during follow-up was significantly lower in the rate-control group vs the rhythm-control group (73% vs 80%; \(P<.001\)). Anticoagulation was encouraged but not mandated in the rhythm-control group after 4 weeks in sinus rhythm, and there was a trend toward higher mortality in the rhythm-control group (27% vs 26%; \(P=.08\)).

Patients <65 years were excluded from the AFFIRM trial. When younger patients experience significant symptoms, early referral to Cardiology should be considered to discuss the long-term benefits and risks of a rhythm-control strategy. Regardless of age, when patients remain symptomatic despite rate- or rhythm-control management, the strategy should be changed.

### Rate-control targets and options

Target heart rates should be individualized. The 2014 ACC/AHA/HRS guideline recommends a resting target heart rate <80 beats per minute (bpm) in symptomatic patients. In patients with permanent AF who remain asymptomatic at higher resting heart rates, a more lenient rate-control strategy (resting heart rate <110 bpm) has demonstrated outcomes equivalent to those of a more strict approach (resting heart rate <80 bpm and heart rate during moderate exercise <110 bpm). Pharmacologic rate-control options include beta-blockers, nondihydropyridine calcium channel antagonists, and digoxin (TABLE 3). Digoxin is associated with increased all-cause mortality in patients with AF regardless of HF status (HR=1.4; 95% CI, 1.2–1.6, \(P=.0001\)). Digoxin should be reserved for patients who are sedentary or have inadequate control with first-line medications.

### Indications for rhythm control

The NICE guidelines, which are consistent with the ACC/AHA/HRS guidelines, recommend rate control as the first-line strategy for AF management, except in people:

- whose AF has a reversible cause
- who have HF believed to be primarily caused by AF
- with new-onset AF
- with atrial flutter that is considered suitable for an ablation strategy to restore sinus rhythm
- for whom a rhythm-control strategy would be more suitable based on clinical judgment.

In addition, patients who continue to experience symptomatic AF despite an adequate trial of rate control should be offered rhythm control.

#### Pharmacologic rhythm-control strategies

Antiarrhythmic drugs can be used for chemical cardioversion, reduction of paroxysms, and long-term maintenance of sinus rhythm. The most commonly used antiarrhythmic drugs are Class IC and Class III agents (TABLE 3). Tailored drug selection for each patient is key. Patients with left atrial diameters >4.5 cm are less likely to remain in sinus rhythm, and patients with left ventricular hypertrophy are at increased risk for proarrhythmic adverse effects. Patients with paroxysmal AF may be candidates for a “pill-in-the-pocket” strategy using propafenone or flecainide.

AF frequently progresses from paroxysmal to persistent and can subsequently result in electrical and structural remodeling that becomes irreversible over time. The patient with uncontrolled symptoms despite attempts at rate control and rhythm control should be promptly referred to an electrophysiologist.

#### Surgical interventions for rate or rhythm control

Electrophysiology interventions include AV nodal ablation with pacemaker placement for rate control, or catheter-directed ablation (radiofrequency or cryotherapy) for rhythm control. CA appears to be more effective than pharmacologic rhythm control. Treatment with CA is indicated for symptomatic paroxysmal AF when a rhythm-control strategy is desired and the AF is refractory to, or the patient is intolerant of, at least one class I
or III antiarrhythmic medication. With these same caveats, CA is a reasonable strategy for symptomatic persistent AF.

Consider more invasive interventions, such as an atrial maze procedure, when patients require cardiac surgery for another indication. Patients with an increased risk of thromboembolism (based on CHA2DS2-VASc) remain at high risk even after successful ablation. As a result, some guidelines recommend continued long-term anticoagulation following CA.\(^6\)

CORRESPONDENCE
Philip Dooley, MD, University of Kansas School of Medicine–Wichita Family Medicine Residency at Via Christi, 707 North Emporia, Wichita, KS 67207; philip.dooley@via-christi.org.

ACKNOWLEDGMENTS
We thank Professor Anne Walling, MB, ChB, FFPHM, Department of Family and Community Medicine, University of Kansas School of Medicine–Wichita for her suggestions and critical review of an earlier version of this manuscript.

References


